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Leukemia is a type of blood cancer and one of the most common pediatric cancers.  
T cell acute lymphoblastic leukemia (T-ALL) accounts for nearly 10-15 % and among 
pediatric patients. Chemotherapy is widely used to treat this cancer. The first line 
treatment of chemotherapy is induction phase where the glucocorticoids are used as 
chemotherapeutic drugs. DNA methylation changes can be associated with the cancer 
progression. Glucocorticoid binds to a glucocorticoid receptor and regulates the 
transcriptional activities. This can result in the upregulation or downregulation of the gene 
expression.  
The objective of this study is to understand the DNA methylation and transcriptome 
changes that are caused by glucocorticoid treatment in T-ALL cells. To achieve this 
objective, CCRF-CEM, a T lymphoblastoid cell line was used. The cells were treated 
with dexamethasone for 48 hours and 72 hours. RRBS libraries were prepared and the 
sequencing data was analysed using DNA methylome analysis pipeline. RNA sequencing 
data was analysed to study the gene expression changes. The functional enrichment of the 
gene ontologies and pathways was studied for these differentially expressed genes. DNA 
methylation status of the glucocorticoid receptor was studied by targeted bisulfite 
pyrosequencing.  
There were 28,395 genes present at both the time points. Statistically filtered gene list 
resulted into 538 upregulated and 2119 downregulated genes for 48 hours treatment. 
Whereas 1669 upregulated genes and 3290 downregulated genes for 72 hours treatment. 
Based on functional over-representation analysis the genes were enriched in several 
molecular functions, biological process and cellular components. The DNA methylation 
status of NR3C1 showed 1% methylation in majority of the sites showing response to 
dexamethasone treatment.  The treatment does not cause epigenetic silencing of the 
NR3C1 gene through DNA methylation. This indicates that the cells were not resistant to 
the glucocorticoid treatment. DNA methylome analysis was done using bioinformatics 
tools and pipelines. However, the MspI enzyme digestion was not successful as the kit is 
yet to be optimized. Hence, the RRBS data was not sufficiently reliable.  
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1.1 T- cell acute lymphoblastic leukemia differentiation  
Leukemia is a type of blood cancer and one of the most common pediatric cancer. 
Lymphocyte precursors are originated as stem cells in the bone marrow and T-cell 
differentiation process takes place in the thymus gland resulting into mature and 
functional T-cells. The matured T- cells enters into the blood stream and are allowed to 
circulate freely in the blood with other lymphatic and non- lymphatic organs (Karrman et 
al., 2017). Epigenetic changes during the maturation of the thymic precursors can cause 
T- cell acute lymphoblastic leukemia (T-ALL) or T- cell lymphoblastic lymphoma 
(Swerdlow et al., 2008) or in the B cell lineage to B-ALL. Typically, ALL is divided in 
to BALL with B cell origin and T-ALL with T cell origin. This malignancy occurring 
from thymus propagates via bone marrow, peripheral blood, lymph nodes and central 
nervous system (Karrman et al., 2017).   
 
Hematopoietic stem cells (HSCs) present in the bone marrow are self-renewing cells. It 
has the ability to get differentiated majorly into myeloid and lymphoid progenitors. 
(Birbrair et al., 2017). Lymphoid progenitors lineage consists of T-cells, B-cells and 
natural killer cells. Myeloid progenitors are differentiated into granulocytes, macrophages 
and platelets. Red blood cells are known as erythrocytes and are also originated from 
HSCs.  The process of production of various types of blood cells and components is 
known as hematopoiesis (Lodish, 2003) 
 
Pediatric ALL involves the transformation of lymphocyte progenitor cells into malignant 
clones and expansion into leukemic cells in T cell or B cell lineages. Lymphocytes has 
the property of fighting with infections (Inaba H, 2013). Our body has a mechanism to 
control the generation of number of lymphocytes, however in ALL the normal generation 
of lymphocytes as well as the control on number of cells turns to be abnormal (Terwilliger 
et al., 2017).  There can be various factors that can cause paediatric leukaemia. The 
environmental exposure to ionizing radiation or genetic predisposition caused due to 
germline mutation are suspected to be among potential causes (Karrman et al., 2017). A 
lymphoblast can gain several alternative mutations that can affect the development and 
proliferation (Terwilliger et al., 2017). T cell acute lymphoblastic leukemia accounts for 
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nearly 10-15% among the total ALL cases that are diagnosed.  (Hjalgrim et al., 2003; 
Siegel et al., 2012). Also, in the case of the pediatric patients, T-ALL comprises 12 to 
15% of diagnosed ALL cases (Raetz & Teachey, n.d., 2016) 
 
1.2 Importance of studying T- cell acute lymphoblastic leukemia 
The over-all survival rates of ALL are approximately 70 % to 80 % (Karrman et al., 2017). 
The survival rates of adults are comparatively higher than pediatric patients (Raetz & 
Teachey, n.d., 2016). The relapse accounts for 15% to 20% of the pediatric patients who 
receives the treatment of ALL and after reaching the initial phase of complete remission, 
the disease relapses (Raetz & Teachey, n.d., 2016). For the T-ALL cases, the disease 
typically goes into remission within two year diagnosis but if replased, the disease 
remains very complicated to be treated, having survival rates lower than 25% (Raetz & 
Teachey, n.d., 2016). In such situation, the only known treatment is hematopoietic cell 
transplantation. However, the successful remission reinduction has always remained as a 
significant challenge. The reinduction remission rates in T-ALL are 30-40% (Raetz & 
Teachey, n.d., 2016). Those people who have suffered relapse of the ALL after the first 
stage of treatment tend to respond poorly to the chemotherapy. Hence, it is a great 
challenge for the research to find a novel cure in the recurrent disease and to understand 
the mechanism of the disease. 
 
1.2.1 Chemotherapy in cancer treatments 
Chemotherapy is a treatment that is commonly used to treat different types of cancer. 
Treatment of different types of cancer require different chemotherapeutic agents 
depending on the chemotherapy regimens.  A number of methods are used while 
providing chemotherapeutic drugs. It can either be curative intent, life prolonging or as 
palliative medicine (Johnstone et al., 2002). The first line of treatment in chemotherapy 
is using chemotherapeutic drugs in the induction phase. This can be considered as curative 
intent (Alfarouk et al., 2015). Consolidation phase in chemotherapy is given after the 
successful remission to ensure that all the residues of cancer cells are eliminated from the 
body. Sometimes, a combination of treatments is also used depending on the type of 
cancer (Alfarouk et al., 2015). In addition to chemotherapy, this can include surgical 
and/or radiation therapy. Last step of the chemotherapy treatment is maintenance phase. 
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This particular phase of the treatment requires a long duration. This is conducted using 
lower amount of chemotherapeutic drug doses to ensure a prolong remission as well as a 
precautionary measure of relapse. The palliative care is also important treatment in 
chemotherapy. It is used to for serious and complex illness by increasing the life 
expectancy of the patient and reducing the tumor load (Zhukovsky, 2019)  
 
The induction therapy helps to restore normal haematopoiesis and the backbone of this 
therapy are corticosteroids, anthracycline and vincristine (Narayanan, 2012). The 
improvements in chemotherapy assures the complete remission rates of 98% in pediatric 
cases and 85% in adults (Terwilliger, 2017). As shown in table 1, the three stages of 
chemotherapy that are required for successful recovery. 
 
Table 1: The three main stages of chemotherapy: induction, consolidation and 
maintenance. The drugs used for each phase of treatment and the approximate time period 
of the treatment given at specific time intervals  
 
Induction Consolidation Maintenance 
The first line treatment 
of cancer using 
chemotherapeutic drug.  
 
To get rid of cancer cell 
left over cancer residues 
or cells. 
 
To decrease the risk of 
relapse and ensure long 














Treatment period is 5 – 6 
weeks 
 
Treatment period is 7 – 9 
months 
 







1.2.2 Side effects of chemotherapy  
Chemotherapy has wide range of side effects. The chemotherapy patients are more 
vulnerable to infections. It can severely affect one’s immune system by reducing the white 
blood cells, platelets and red blood cells. In some cases of myelosupression, there is 
severe loss of bone marrow stem cells that are almost destroyed and might need cell 
transplant. Such patients with immune system suppression suffers severe gastrointestinal 
complications of chemotherapy. The common symptoms of the gastrointestinal infections 
are nausea, diarrhea, vomiting, fever or abdominal pain (Davila, 2006). These type of 
complicated infections remains fatal if not treated on time. Due to frequent vomiting 
during gastrointestinal infections, a patient suffers malnutrition and dehydration leading 
to weight loss and weakness (Davila, 2006). Hair loss is one of the major side effects seen 
in the patients undergoing chemotherapy treatment (Al-mohanna & Al-khenaizan, 2010). 
The chemotherapy drugs are meant to destroy the rapidly growing cells and hence, it 
impairs any kinds of cell divisions in body. However, the hair can be regrown after the 
treatment. Anemia is also another major side effect. Apart from these major side effects, 
there are many other side effects of chemotherapy such as infertility, fatigues, organ 
damage or failures, allergies etc ((Brydøy et al., 2009), (Neel et. al., 2015)) 
 
Previous studies have shown that the pediatric ALL patients can develop neurocognitive 
and psychological defects after undergoing a chemotherapy treatment. Working memory 
and memory processing speed can get impaired. The motor function and IQ level of the 
children undergone chemotherapy can decrease. A particular study conducted with 
corticosteroids have suggested that the pediatric patients tend to have changes in behavior 
and hippocampal functioning. Hence, in long term the neurocognitive functions are 
severely impaired for paediatric patients as a side effect of chemotherapy (Neel et. al., 
2015). 
 
Glucocorticoids play a key role in CNS leukemia (central nervous system) control in 
clinical treatments. There have been constant efforts to minimize the use of cranial 
radiation therapy for the pediatric ALL patients. Various studies have been conducted to 
successfully replace cranial radiation therapy with systemic and intrathecal chemotherapy 
in T-ALL patients as well as for CNS disease (Iyer et al., 2015). Dexamethasone shows 
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a major impact in such treatments due to its loner half- life and higher ability to penetrate 
the CNS along with anti-inflammatory features. Hence, dexamethasone is increasingly 
used in the treatment of T-ALL instead of cranial radiation therapy. Few studies directed 
towards the comparison of dexamethasone and prednisone have suggested that 
dexamethasone is more effective than prednisone to prevent CNS relapse in T-ALL and 
B-ALL(Iyer et al., 2015).  
 
1.2.3 Glucocorticoids in chemotherapeutics  
Glucocorticoids (prednisone and dexamethasone) are considered to be important in the 
clinical treatment of ALL and were among the first drugs that were used in the treatment 
of the disease (Hiroto, 2010). Dexamethasone is an analog of cortisol with a half-life of 
36 to 72 hours. Previous studies have shown that, in comparison to prednisolone, 
dexamethasone has higher and better ability to generate response in CNS (Möricke,2016). 
However, although there is a reduction in relapse rate and improved survival rates, use of 
dexamethasone is associated with increased the risk of adverse effects when compared to 
use of prednisone (Möricke,2016). The binding of glucocorticoids to the receptors takes 
place in the cytoplasm. The glucocorticoid receptor homodimerize due to binding and 
translocate to nucleus. Further, the transactivation of gene expression occurs when these 
homodimers interact with glucocorticoid response genes. Sometimes it can be monomeric 
form and supress the transcription factors. Both, homodimeric and monomeric processes 
can lead to various outcomes such as inhibition of cytokine production, apoptosis or alter 
the oncogene expression. (Oasa et al., 2018) 
Glucocorticoids are used in clinical practices as it is efficient to eliminate the cancerous 
cells but around 20% of the patients with T-ALL possess glucocorticoids resistance; 
either acquired or de novo. Resistance in the initial phase of the chemotherapy does not 
ensure the remission of the treatment and has high chances of the relapse of the disease. 
There is no evidence yet for the glucocorticoid resistance but the drug resistance might 
depend on alterations or mutations in the genetic and epigenetics regulations. (Jan et al., 
2013).  
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1.3 Regulation of glucocorticoid receptors expression 
NR3C1 is very rich in GC (72%) and the promoter region of this GR has been widely 
studied (Vandevyver et al., 2014). GC binds to GR and GR tends to alter its conformation, 
travels to the nucleus and starts gene transcriptions (Wandler et al., 2020). Whereas 
unbound GRs remains free in cytosol. This can result into up regulation or down 
regulation of various genes. In humans, the GR protein, NR3C1 is present on chromosome 
5 and is a receptor where the glucocorticoids can bind  (Vandevyver et al., 2014).  
The NR3C1 gene has 9 exons. Among these, one exon is responsible for 5’ UTR and 
remaining are GR proteins. There are 13 hGR in the exon-1 variants present in upstream 
of the promoter region (Vandevyver et al., 2014). Such promoters are responsible for 
alteration in the expression levels of GR proteins. These promotors consist of binding 
sites for transcriptional factors, interferon regulatory factors and GR itself for maintaining 
the regulation. Also, these variants can affect epigenetic regulation. DNA methylation 
and histone modifications are influenced by these exon variants. Based on the changes in 
these modifications and methylation status, GR gene expression levels can vary 
(Timmermans et al., 2019). The resistance towards GC can also be understood by these 
epigenetic modifications. 
The GR interferes the function of glucocorticoids in the cells. The GR belongs to nuclear 
receptor superfamily of transcription factors. Glucocorticoids uses cellular and tissue 
specific effects because of different isoforms of receptors (Timmermans et al., 2019). The 
GR regulates the gene expression of the genes that are sensitive to GC by upregulation or 
downregulation. Approximately 1000 to 2000 genes are influenced by GR regulation. 
Previous studies have reported that 20% of the total genes are influenced by GR in either 
of the ways (Timmermans et al., 2019).  
There is a loss of GR expression levels have been confirmed CRISPR/Cas9 gene editing 
(Wandler et al., 2020). Glucocorticoid treatments, when given to the drug sensitive T-
ALLs in vivo have resulted into changes in the transcript levels of many genes. This 
response was reduced in the T-ALL relapse (Wandler et al., 2020). Hence, drug sensitive 
T-ALL patients are more likely to have reduced GR expression due to compromised 
glucocorticoids responses and/or mutations in NR3C1. This could be an important reason 
for the resistance of dexamethasone in T-ALL and several other leukemias (Wandler et 
al., 2020).  
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1.3.1 Regulation of previously identified gene candidates  
In, transcriptional control of GR coding NR3C1 gene for eukaryotic cells, RNA levels 
are responsible for the expression of protein levels. The expression of gene is regulated 
by transcriptional activities. GR shows different gene expression patterns for various cells 
based on the differential regulation. For NR3C1, the promoters consist of NFƙB, AP-1, 
AP-2, cAMP element binding, NF1/CTF1, IRF1/2 and EGR1. These transcriptional 
factors are required for the up regulation of the genes whereas GC responsive factor-1 
and c-Ets-1/2 are responsible for repression. Along with these TFs, small non coding 
RNAs are also present in the regulation as RNA can supress the gene expression by 
binding to complementary region in DNA. nGRE is also involved in the downregulation 
of GR. Higher dosage of glucocorticoids tends to repress the GR expression levels leading 
to resistance and unresponsiveness. Hence, various TFs binding to NR3C1 gene can gave 
different expressions (Timmermans et al., 2019) 
BTG1 and BTG2 have been reported crucial for cell signalling pathways and promoting 
either death or survival of the cell. These are important tumor supressors in malignancies 
like lymphoid. The recent studies have also reported that BTG1 and BTG2 can be used 
as biomarkers of different types cancer prognosis. mRNA expressions of BTG1 and 
BTG2 are regulated by miRNA (Li, Choi, Casey, Dill, & Felsher, 2014). They are located 
in the nucleus and cytoplasm and cellular trafficking interferes its activities (Kawakubo 
et. al., 2006). Deregulation of BTG1 and BTG2 is observed in malignancies and prognosis 
of disease. However, further investigation is yet required to study their complex role in 
cancers. BTG1 tends to interact with protein arginine methyl transferase (PRMT1). Such 
enzymes are known to be global gene regulators. BTG1 is critical for glucocorticoid 
induced therapy response in vitro that is regulated by GR. The BTG1 and PRMT1 
together positively upregulated GR signalling in leukemia cells. The detailed study has 
not yet been investigated. BTG2 also interects wih PRMT1 and influences the 
transcriptional activation and differentiation (Van Galen et. al., 2010) 
Tumor protein 53 induced nuclear protein 1 (TP53INP1) is p 53 target gene. The 
expression of this gene is regulated by p53 and E2F1 transcription factor. It is anti-
proliferative and crucial for DNA damage response and cell homeostasis (Shahbazi et al., 
2013). This gene gets downregulated in the organ cancers as it is tumor suppressor gene. 
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Lack of TP53INP1 can cause tumorigenesis and repression of this gene indicates early 
signs of cancer (by miR-55). The gene expression is often silenced in cancer cells causing 
tumor growth but restoration of this gene expression can inhibit the malignancy growth 
due to its anti -proliferative properties (Shahbazi et al., 2013). E2F1 is responsible for 
huge number of gene expression regulations and is necessary for progression from G1 to 
S (Weinberg, 2011). Previous studies have reported that increased in the activity of E2F1 
transcription factor correlated with increase in the expression of TP53INP1 and other 
apoptosis co factors. The upregulation of TP53INP1 can take place in p53 independent 
mechanism instead of p53 dependent mechanism(Shahbazi et al., 2013). ChIP assys have 
confirmed that the gene core promoter region of TP53INP1 binds to E2F1and activates 
gene transcriptional activities (Hershko et. al., 2005). The E2F1 transcription factor is 
essential for cell progression but the underlying mechanism is yet to be investigated to 
study the mechanism of TP53INP1 gene expression by E2F1. 
Previously identified candidates, that shows GC induced gene expression changes are 
FKBP5 and DDIT4. FKBP5 is an important indicator of GC sensitivity. It is also a GR 
co- chaperone and is transcriptionally activated by glucocorticoids (Schmidt et al., 2016). 
When induced by GC, it competes with FKBP2 for binding sites. This results into 
decrease of nuclear transport of receptors that are ligand bounded and also decreases the 
transcriptional activity of GC. If cells over express FKBP5, it suggests that FKBP5 is 
resistant towards GC induction.  Similar study with DDIT4 suggest its over expression 
causes decrease sensitivity for dexamethasone induced apoptosis. (Schmidt et al., 2016; 
Timmermans et al., 2019). 
 
1.3.2 Epigenetics in Cancer 
When methyl groups are added to the DNA molecule, this process is known as DNA 
methylation. DNA methylation causes alteration in the activity of DNA and when it is 
present in the gene promoter region, methylation causes repression of gene transcription. 
The modification of epigenetic mechanisms which plays an important role to modify the 
chromatin structure consists of DNA methylation, covalent histone modifications, non-
coding RNAs like miRNA and non-covalent mechanisms like histone variants or 
nucleosome remodelling. These modifications are responsible to regulate the genome by 
causing alteration of chromatin structures and its compactness along accessibility 
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(Ranjani, 2016). This interplay of modifications is also considered to be responsible for 
cell types, various developmental stages and disease initiation states like cancer. This 
patterns are cellular identity at different states during development (Sharma et al., 2010) 
DNA methylation is one of the mechanisms, which recruits regulatory proteins to DNA 
resulting into gene silencing or activation (Laird et. al., 2013). Aberrant changes in DNA 
methylation can lead to disease initiation state (Weinberg, 2011). Regulation of DNA 
methylation is also very important epigenetic mechanism in cancer initiation, 
maintenance and progression (Ranjani, 2016). During malignant transformation, altered 
DNA methylation that is associated with genomic instability and changes in regulation of 
tumour suppressor genes has been observed (Jessica et. al., 2013).  
 
Cytosine methylation in CpG sites is also an important epigenetic modification affecting 
gene expression patterns. Many genes in the genomes of mammals have methylated CpG 
islands in promoter regions (Hartl, 2005). CpG islands occupies approximately 60 to 70% 
of the human gene promoters. Gene expression and development of cell identity are 
regulated by these sites. CpG islands are genomic regions that possess high proportion 
of CpG sites. In some genes CpG island localised in promoter regions can get 
hypermethylated in tissue specific manner during the developmental stages that can lead 
to gene silencing (Weinberg, 2011). CpG hypermethylation is also one of the mechanisms 
regulating inactivation of X- chromosome and imprinting of genes. DNA 
hypermethylation is also important for controlling repetitive sequences and transposons 
that are present in the human genome and helps to maintain a chromosomal stability 
(Chen et al., 2014).  
 
Alteration in the DNA methylation patterns are linked with many diseases like cancers. 
Although several different patterns of CpG methylations for ALL cells has already been 
recognised, the genome wide DNA methylation patterns are still unknown for most of the 
subgroups of ALL. Understanding of the role of abnormal DNA methylation and 
transcriptional regulation is important for the development of new treatments of cancers 
(Lakshminarasimhan & Liang, n.d.). The DNA methylation absence in the CpG sites of 
gene promoter often indicates active gene transcription. Abnormal DNA methylation is 
general phenotype of cancer. Identification of such alterations in cancer phenotypes can 
contribute in the field of therapeutics (Lakshminarasimhan & Liang, n.d.).  
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1.4. DNA methylome analysis for cytosine status 
DNA methylation studies are essential to investigate the epigenetic modifications as it  
contributes to the regulation of genome and several other biological processes. It is also 
related to multiple diseases phenotypes and cancers. However, there are many ways to 
carry out the DNA methylome analysis but one of the most preferred method by 
researchers is to identify the cytosine resides that are methylated in the target sample and 
also to check the methylation status at these sites of interest. Whole genome bisulfite 
sequencing (WGBS) is a high through put technology that is used for studying DNA 
methylation of cytosine for the entire genome. Single cytosine can be determined by 
bisulfite conversion treatment of the DNA before sequencing (Stevens et al., 2013). 
However, it is cost effective as well as time consuming. Hence, a new method was 
introduced known as RRBS for the genone wide DNA methylation assays. It focuses on 
the part of genome, rather than entire genome which is low cost DNA sequencing.  
 
1.4.1 Reduced representation bisulfite sequencing (RRBS) 
Reduced representation bisulfite sequencing (RRBS) is an efficient high throughput 
method that is used to analyse the genome-wide methylation profiles. It uses restriction 
enzymes and bisulfite sequencing to enhance areas of the genome with high CpG content. 
Mspl digestion recognizes the specific recognition sites (5’ C/CGG 3’ and 3’ G/GCC 5’) 
and cuts them. This results into fragments only with CG located at ends of fragments. 
Hence, it encourages the CpG rich regions from entire genome to be sequenced rather 
than whole genome. This way, it decreases the load and amount of sequencing. This 
method is cost effective (Babraham Bioinformatics, 2013). The RRBS samples are 
prepared by digestion of genomic DNA with a restriction endonuclease Mspl followed 
by end-repair, adapter ligation and bisulfite conversion. Bisulfite sequencing is used for 
treating the DNA before performing the sequencing. This is done to obtain methylation 
patterns of DNA. Bisulfite conversion is efficient to convert this cytosine to uracil during 
the bisulfite treatment of DNA, but does not affect 5-methylcytosine residue. Hence, 
unmethylated cytosines gets converted into uracil during the PCR reaction and displayed 
as thymine after bisulfite treatment as a result of amplification of sense strand and 
adenines in antisense strands. Cytosine remains unaffected if it is methylated and gets 
converted to uracil (later displayed as thymine) if unmethylated. The bisulfite conversion 
14 
reveals specific information about the DNA sequences that correlates with DNA 
methylation patterns and cytosine methylation status (Babraham Bioinformatics, 2013). 
 The method yields information on majority of CpG islands of genome. But the fairly 
small size fragments of RRBS can become a problem when the reads are with high read 
lengths. For the read length longer than Mspl fragment, the sequencing read can cause an 
error and it might continue to read the adapter sequence on 3’ end. The reads might not 
get aligned at all (reduced mapping efficiency), incorrect methylation calls or, in the worst 
case, mis-alignments (which will most likely also generate incorrect methylation calls). 
RRBS libraries with long read lengths suffer more from all of the above due to the short 
size- selected fragment size (Babraham Bioinformatics, 2013)  
http://www.bioinformatics.babraham.ac.uk/projects/bismark/RRBS_Guide.pdf 
Paired-end DNA sequencing reads gives high quality alignment of the DNA regions that 
contains repetitive sequences and also detects DNA mutations like insertions, deletions 
and inversions. The paired-end reads show increased mapping efficiency when compared 
to single-end reads, but when using long sequencing length, it faces a problem of getting 
potentially redundant methylation. Because redundant overlapping in paired end not only 
represents twice number of reads but also it shows twice many methylation calls. Hence, 
to avoid overlapping, redundant methylation is to be discarded at certain coverage by 
independent reads and this makes paired-end RRBS reads difficult due to overlapping. In 
contrast, single-end with similar number of reads to paired-end reads tend to yield better 
and more genuine methylation information until it allows significant mapping efficiency 
(Babraham Bioinformatics, 2013). 
As for high throughput sequencing, it is recommended to use quality control on the data 
to remove problems and analyse the RRBS libraries to avoid errors or directional/non 
directional biases. Trim Galore is used as a wrapper script to automate quality and adapter 
trimming. This also performs quality control and functions to remove biased methylation 
positions of RRBS sequence files. For Mspl digested RRBS libraries, Trim Galore works 
on quality and adapter trimming into two steps. It allows to remove two additional bases 
containing cytosine that were introduced during library preparation. For fastQ files, it can 
perform single pass adapter and quality trimming. (Babraham Bioinformatics, 2013).  
https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/ 
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1.4.1.1 Bismark: Bisulfite Read mapper 
Bismark is a flexible tool for efficient analysis of BS-Seq data performing map reading 
and methylation in one step (Felix, 2011). Generally, bisulfite treatments of DNA do not 
effect methylated cytosines but converts non-methylated cytosines to uracils. Bisulfite 
treatment along with PCR amplification generates four strands of DNA. Thus, mapping 
these bisulfite- treated sequences to reference genome faces challenges like complexity 
reduction of DNA code, all four reads can exist in all methylation sites. For bisulfite 
libraries there are two possibilities. Directional sequencing library and non-specific 
(contains four roughly sequenced strands). For this non-specific bisulfite reads, Bismark 
finds a unique alignment by running these alignment processes. The reads are transformed 
and then aligned to pre-converted forms of reference genome. This map reading allows 
Bismark to determine the strand origin of bisulfite read. Bismark can handle single and 
paired-end mapping of directional/non-directional bisulfite libraries. (Babraham 
Bioinformatics, 2016)  
https://www.bioinformatics.babraham.ac.uk/projects/bismark/ 
1.4.1.2 Penalized Quasi-Likelihood for sequencing count data (PQLseq) 
PQLseq enables heritability estimation and differential analysis with the help of 
generalized framework of linear mixed models (Shiquan, 2013).  It is used as R software 
package with parallel computing ability. This can accommodate predictor variables and 
can include technical or biological covariates as fixed effects. Using the real data 
applications along with simulations, it has become a useful tool for the analysis of 
genomic sequencing datasets (Shiquan, 2018).  
1.4.2 Targeted bisulfite pyrosequencing 
Targeted pyrosequencing is a method of DNA sequencing that is based on the principle 
of ‘sequencing by synthesis’ where the sequencing is done with checking the nucleotides 
that are incorporated using DNA polymerase along with chemoluminescent enzyme 
(Jorg, 2007). The pyrosequencing depends on light detection which is a chain reaction 
when the pyrophosphate is released.   
Pyrosequencing enables the study of CpG sites using bisulfite conversions. The cascade 
of reaction consist of ssDNA (PCR amplicon used as template), DNA polymerase, ATP 
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sulfurylase, luciferase and apyrase, Adenosine phosphosulfate (APS) and luciferin 
(Delaney & Arbor, 2016)  
A sequencing primer is annealed to ssDNA. A nucleotide (from dNTPs) is incorporated 
to the growing strand with the help pf DNA polymerase and this causes the release of 
pyrophosphate (PPi). ATP sulfurylase enzyme converts this PPi to ATP that is able to 
now activate luciferase enzyme. This activation of luciferase enzyme can catalyse the 
conversion of luciferin to oxyluciferin and light. The light peak depends on the amount 
of nucleotide that is added to the growing chain and is captured by camera inbuild camera. 
The unwanted nucleotides present in the sample is degraded by apyrase enzyme and 
nucleotide is dispensed. C to T ratio of light peaks at CpG site displays accurate amount 
of methylation at the specific site in the sample (Delaney & Arbor, 2016).  
1.4.3 RNA sequencing overview 
RNA sequencing (RNAseq) is a technology that is based on NGS to measure the presence 
of RNA in the sample and further analyse the cellular transcriptomes (Corey, 2012). 
Transcriptome comprises of RNA transcripts, coding and non-coding RNAs. Also the 
single cell transcriptomics is a novel approach that analyses the gene expression level of 
each cell in the population by measuring the mRNA concentration (Wang et. al., 2009). 
RNAseq involves conversion of mRNA to a library of cDNA during sample preparation. 
This cDNA is fragmented using enzymes or sonication. Later, the size selection is carried 
out, linkers are added and sequencing performed. The high throughput sequencing 
commonly generates short reads. These reads are aligned to reference genome to identify 
the genes that were transcribed. Gene annotation is later conducted the gene expression, 
differential gene expression levels and alternative splicing. (Griffith, 2015). 
Downstream analysis of RNAseq includes the finding of differential gene expressions 
between several treated samples. The genes can be either upregulated or downregulated. 
Various tools are used to determine differential gene expression, such as R. Further to 
obtain more details, functional gene set enrichment analysis (GESA) or over-
representation analysis can be performed.  
G: GOSt is an efficient tool for the statistical enrichment analysis of the genes. It is used 
to find over representation of the genes from gene set pathways like Gene Ontology terms, 
KEGG pathways and other biological processes, human proteins and protein-protein 
interactions. G: Profiler supports an ordered query for the gene list provided by the users 
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and gives an output in the order of decreasing importance. Such an ordered result can be 
biologically meaningful for the interpretation and analysis of the study (Peterson et al., 
2019).  With functional enrichment analysis, either gene enrichment analysis or over-
representation analysis one can study enrichment of genes in functional or other 
annotation categories and obtain information of putative functional significance of 
observed transcriptional changes. The GO annotations consists of three subcategories: 
molecular functions, biological process and cellular components. The biological 
pathways databases like KEGG and Reactome are also supported by g: GOSt. These are 
curated by domain experts (Peterson et al., 2019). (https://biit.cs.ut.ee/gprofiler/convert) 
  
1.5 Aims and Objectives  
The goal of this study is obtain a better understanding of the molecular mechanism of 
glucocorticoid response in pediatric T-ALL cells, because glucocorticoids are important 
in therapeutic process of T-ALL. The study also majorly aims to understand the DNA 
methylation and gene expression changes that are caused by glucocorticoids treatment. 
The specific aims are to identify: 
1. DNA methylation status of NR3C1 gene in T-ALL cells. 
2. DNA methylation changes caused by glucocorticoids treatment in T-ALL cells 
3. Gene expression changes caused by glucocorticoids treatment in ALL cells, 
4. To investigate the molecular mechanisms how glucocorticoid treatment modulates 
gene expression changes through DNA methylation.   
1.6 Significance of the study  
The study was conducted to understand the dexamethasone response in paediatric T- cell 
acute lymphoblastic leukaemia and to investigate the influence of dexamethasone 
treatment on NR3C1 DNA methylation, gene expression and DNA methylome in T-ALL 
cells. In my study, I have used the bioinformatics pipeline to investigate the transcriptome 
changes caused by to dexamethasone treatment. The functional enrichment gene sets and 
pathways for the differential gene expressions have been identified. This study may be 
useful in understanding the initial mechanism of glucocorticoids and its response towards 
T-ALL cells. This knowledge might be useful for developing an improvement in the 
treatment of TALL with lesser toxic side effects. It would be a relief for the pediatric 
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patients who undergoes chemotherapy and suffers long term side effects well as their 
family. 
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2 Materials and Methods  
2.1 Cell culture  
For the experiment, CCRF-CEM (ATCC) is a T lymphoblastoid cell line derived by G.E. 
Foley, et al. was used. The base medium for the cell line was RPMI-1640 Medium, 
ATCC 30-2001 10 % FBS and 1 % L-glutamine. The cells were treated in the presence 
of 1 µM Dexamethasone (Sigma, D4902) and a control vehicle (EtOH) for 48 h and 72 
h. Cultures were maintained by the addition of fresh medium or replacement of medium 
in an incubator with 5% CO2 at 37 ºC.  The density of cultures was maintained between 
2 to 3 X 105 and 1 to 2 X 106 viable cells/mL. The cells were collected and the replicates 




2.2 Targeted DNA methylation analysis 
MinElute DNA spin columns, DNA Protect Buffer, and Buffer BD from the EpiTect Fast 
DNA Bisulfite Kit (cat.  nos.  59824 and 59826) is  stored  at  2 to 8°C. Bisulfite 
conversion reaction set up was done at room temperature.  
The DNA samples were thawn and bisulfite solution was vortexed prior use. PCR tubes 
were used to set up the reaction. The reaction was prepared as shown in the table 2. While 
adding the buffer, the reaction colour changed to blue which is an indicator of correct pH 
for bisulfite conversion reaction. The reaction tubes were placed in the thermal cycler for 
bisulfite conversion with conditions shown in table 3. (Refer to EpiTect Fast Bisulfite 
Conversion manual) 
 
Table 2: Calculations based on the sample concentrations.  
 









1 C1W1 48 64 3.125 16.87 
2 D1W1 48 56.6 3.53 16.47 
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3 C2W1 48 56.2 3.55 16.45 
4 D2W1 48 48.6 4.11 15.89 
5 C1W2 48 50.6 3.95 16.05 
6 D1W2 48 20.40 9.80 10.2 
7 C2W2 48 40.6 4.92 15.08 
8 D2W2 48 24.2 8.26 11.74 
9 C1W1 72 36.8 5.4 14.6 
10 D1W1 72 50.4 4.0 16 
11 C2W1 72 40.6 4.92 15.08 
12 D2W1 72 41.4 4.83 15.17 
13 C1W2 72 49.2 4.06 15.94 
14 D1W2 72 54.8 3.64 16.34 
15 C2W2 72 34.2 5.84 14.16 
16 D2W2 72 40.2 4.97 15.03 
*Note: The replicates were used for the experiment. Two control sample (C1 and C2) 
treated at 48 hours and 72 hours indicates the replicates (W1 and W2). Similarly, for 
dexamethasone treated samples (D1 and D2) at different time points and replicates were 
used. 
For high concentration of DNA (1ng- 2 μg), 20 μl of the DNA is used. RNAse free water 
could be variable depending upon the total volume of the reaction. Bisulfite solution, 85 
μl was added to convert unmethylated cytosines into thymines along with 35 μl of DNA 
protect buffer. DNA protect buffer prevents DNA fragmentation leading to effective 
DNA denaturation and results into single stranded DNA required for cytosine conversion.  
 
Table 3: Bisulfite conditions for thermal cycler 
 
Step Time (minutes) Temperature (°C) 
            Denaturation 5 95 
Incubation 10 60 
            Denaturation 5 95 
            Incubation 10 60 
            Hold Infinite 20 
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The reaction tubes were centrifuged after the bisulfite conversion. The reaction mixture 
was transferred to 1.5 ml microcentrifuge tubes and freshly prepared 310 μl BL buffer 
was added to each sample and vortex briefly. Fresh ethanol (96-100%) 250 μl was added 
to each sample and mixed by pulse vortexing for 15 s. The tubes were centrifuged at 
maximum speed (13,000 rpm) to spin down the drops from lids. MinElute DNA spin 
columns were placed in the collection tubes and the reaction mixture was transferred to 
the corresponding spin column. The tubes were centrifuged at maximum speed for 1 min 
and the flow through was discarded. The spin column was place back to the collection 
tubes and 500 μl BW buffer was added to each column and centrifuged for 1 min at 
maximum speed. The flow through was discarded again and columns were placed back 
in the tubes.  
To each spin column, 500 μl of Buffer BD was added and was allowed to incubate for 15 
min at room temperature. The spin columns were centrifuged at maximum speed for 1 
min and flow through was discarded, spin columns were placed back to the tubes. To each 
spin column, 500 μl of BW buffer was added and centrifuged for 1 min, discarded the 
flow through and columns were placed back in the tubes. This step was repeated. Chilled 
250 μl of ethanol (96-100%) was added to each spin column and was centrifuged for 1 
min. The spin columns were transferred to new 2 ml collection tubes and centrifuged for 
1 min at maximum speed to eliminate residues of ethanol. The spin columns were placed 
in 1.5 μl microcentrifuge tubes and 15 μl of EB buffer was directly added onto the centre 
of each spin column membrane. This was allowed to incubate at room temperature for 1 
min, centrifuged for 1 min at maximum speed to elute DNA. The DNA eluted was stored 
at 2-8°C for up to 24 h. refer the manual 
(EpiTect Fast Bisulfite Conversion Handbook www.qiagen.com/HB-1211) 
 
PCR using PyroMark PCR master mix  
The PyroMark PCR master mix, coralLoad concentrate and primer solutions were thawn 
at room temperature. The reaction set up was done for the pediatric leukemia samples 
treated with control and dexamethasone at 48 h and 72 h with replicates. (Table 2). 
Additionally, one negative control was added to the set of reaction mixture. The primers 
were ordered from Integrated DNA technologies (IDT). The general properties and 
sequence of the primers are as mentioned in table 4. 
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Table 4: NR3C1 forward and reverse primer sequence and properties. Reverse primer is 
biotinylated at 5’ end to prepare single stranded PCR product for pyrosequencing. 
Pyromark Assay Design software 2.0 was used to design the primers. 
 
 
Properties NR3C1_F1 (forward) NR3C1_R1 (reverse) 
Sequence  5’- GAG TTT TAG AGT 
GGG TTT GGA -3’ 
5’ - /5Biosg/AAA CCA CCC AAT 
TTC TCC AAT TTC TTT -3’ 
Temperature 52.3°C 56.1°C 
GC content 42.9% 33.3% 
Oligo base 25 nmole DNA oligo, 21 bases 25 nmole DNA oligo, 27 bases 
 
 
Table 5: PyroMark PCR master Mix reaction setup. The table shows the composition of 
volumes per reaction. For our experiment, we used the reaction mixture according to the 
sample list (Table 2) along with one negative control.  
 
 
Reaction components Volume/reaction (µl) Final concentration 
PyroMark PCR Master 
Mix 
12.5 Contains HotStarTaq 
DNA polymerase 
Coral Load concentrate 
10x 
2.5 1x 
Forward primer Variable 0.2µM 
Reverse Primer Variable 0.2µM 
RNase-free water Variable - 
Template DNA Variable 10-20 ng/BS conversion 
DNA 





The reaction master mix as shown in table 5 was prepared in the 1.5ml microcentrifuge 
tube and dispensed into appropriate volumes to the PCR tubes (21 µl each). The BS 
converted DNA templates were added to the corresponding PCR tubes (20 ng, 4 µl). The 
reaction set up was transferred to thermal cycler with heated lid.  
 
Table 6: PyroMark PCR master mix optimized cycling program 
 
Initial PCR activation step 15 min 95°C 
Denaturation 30 s 94°C 
Annealing 30 s 56°C 
Extension 30 s 72°C 
Number of cycles 45 cycles 
Final extension 10 min 72°C 
 
The PCR tubes were placed in the thermal cycler with the program set according to table 
6. The amplified product is stored at -20°C for longer storage. To verify the PCR results, 
2 % agarose gel was prepared 100 ml of TAE buffer (1x TAE). For the gel preparation 5 
µl of  SYBR Gold nucleic acid gel stain (10,000 x concentrate in DMSO) was added and 
the gel was allowed to set in the tray for 20 minutes. 5 µl of each sample were loaded in 
the well against 100 bp DNA ladder.  
 
PyroMark Q24 Advanced CpG Assay  
The assay was performed using streptavidin sepharose HP. The solution of streptavidin 
beads was mixed gently until it turns into a homogenous solution. The run set up was pre-
set using PyroMark Q24 Advance software. The reaction set up for the DNA 
immobilization includes 1 µl of Streptavidin Sepharose HP, 40 µl of PyroMark Binding 
Buffer, 20 µl of Biotinylated PCR product and RNAse free water as required to make up 
the total volume upto 80 µl. 
The PCR plate was sealed after adding the reaction components and PCR product to each 
individual corresponding well. The PyroMark Q24 plate (cat. No. 979201) was kept at 
room temperature.  
The lyophilized enzyme Mixture and substrate mixtures were taken. The PyroMark Q24 
cartridge (cat. No. 979202) and the reagents were allowed to reach room temperature. 
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The cartridge was placed in such a way that the label faces in front. The PyroMark Q24 
cartridge was loaded with PyroMark advanced nucleotides, enzyme mixture and substrate 
mixture. (Figure 1) 
 
 
Figure 1: PyroMark Q24 cartridge view from top. The components are added according 
to the designated wells. E: Enzyme Mixture, S: Substrate Mixture and Nucleotides (A, T, 
C, G). The volumes depend on the pre- run set up information.  
 
The Cartridge was placed in the position assigned on PyroMark Q24 advanced instrument 
and the label facing outwards as shown in figure 1. The sufficient amount of sequencing 
primer was added to 0.375µM in PyroMark Advanced annealing buffer. Stock 
concentration 10 mM. The diluted sequencing primer was added to each well of 
PyroMark Q24 plate 20 µl according to the run setup. The PCR plate was placed on 
PyroMark Q24 vacuum work station. The vacuum pump was switched on and the filter 
probes of vacuum tool was placed into the PCR plate slowly upto 15s. The vacuum tool 
was placed onto trough with 40 ml of 70% ethanol for 5s, followed by 50 ml of wash 
buffer for 10 s. The tool was raised at 90° vertical for 5s to drain the liquid from filter 
probes and was switched off when used. The beads were released into PyroMark Q24 
plate by lowering the filter probes into diluted sequencing primer. The tool was 
transferred to trough with high-purity water for 10s and waster was allowed to flush 
through it. The tool was switched off and placed back to its station after use. The 
PyroMark Q24 plate with samples were pre heated at 80°C for 5 min before placing onto 




2.3 DNA methylome analysis study 
 
 
                                                                       







Figure 2: Work flow for the DNA methylome analysis pipeline using corresponding high 
throughput tools. RRBS data is produced from sequencing. The quality control of the data 
is done using FastQC and MultiQC report. Low quality reads are trimmed using trim 
galore. The reads are mapped against reference genome using Bismark and DNA 
methylation changes are identified using PQLseq. 
The aim of the DNA methylation analysis was to understand the glucocorticoid 
mechanism causing changes in the DNA methylation patterns. The analysis was 
performed using RRBS sequencing data, trimming and mapping the reads to the reference 
genome. The mapping of reads gives the comparative study of normal genome and 
methylation profiles of the cytosine. As shown in the figure 2, the work flow of DNA 
methylome pipeline shows the procedure to analyse the data.  
For the generation of my data the libraries had been prepared from the T-ALL samples 
by using 100 ng of genomic DNA and a new kit from Swift Biosciences, which had not 
been tested before. The RRBS samples were prepared by digestion of genomic DNA with 
a restriction endonuclease Msp l followed by end-repair, adapter ligation and bisulfite 
conversion.(Boyle et al., 2012) The libraries were amplified with PCR, purified and 
quality controlled. The next-generation sequencing was performed with Illumina 
NovasSeq 6000 instrument by using 2 x 50 bp chemistry.  The method yields information 






















The data was generated from the sequencing; my aim here was to analysis the data 
produced from RRBS sequencing. However, The RRBS data analysis, trimming and 
mapping the reads to the reference genome was performed by senior researcher from our 
lab.  
The output data from sequencing are FastQ files. To check the quality control of the 
output files, FastQC and multiQC tools were used (Boyle et al., 2012) to trim the 
unwanted background, trim galore was used. Trim galore trims off low quality bases from 
3’ ends of reads before adapter is removed. Minimum number of overlap of adapter 
sequences was set to default 1 but can be variable according to the requirement. 
(www.bioinformatics.babraham.ac.uk/projects/trim_galore/) 
The RRBS data was trimmed and mapped against the reference genome using bismark. 
Bismark aligns the bisulfite treated reads to reference genome along with cytosine 
methylation calls simultaneously. The reference genome (Hg 38) was downloaded. FastA 
format files are supported as input for Bismark. The sequence reads were fully 
transformed into Bisulfite converted forwards and reverse reads. Best fit and unique 
alignment out of the four alignments of sequence reads is selected against bisulfite 
genomes that is simultaneously running. Comparison is made against normal genome 
sequence and methylation profiles of cytosines was studied. The reference link 
(https://www.bioinformatics.babraham.ac.uk/projects/bismark/) 
 
2.4 RNA sequencing data analysis pipeline  
                                                                                                                                                                                                            
    
 
Figure 3: RNAseq data is produced from the sequencing. Galaxy Europe webserver is 
used for the pipeline. The quality control of the data is performed along with trimming 
the low quality reads. The reads are aligned against annotated reference genome and the 
differential gene expression studies of the gene is carried out.  
The aim of studying RNA sequencing data was to understand the transcriptome changes 

















studied using functional enrichment analysis. This results into the most significant terms 
that are enriched.  
RNAseq data already available was used to analyse the transcriptome that contains all 
polyA tailed coding and non-coding RNA transcripts with size over 100 bp. In simple 
terms, the overview of RNAseq is; total RNA extraction of the subsets of RNAs have 
been isolated from the leukemia cells. The libraries had been earlier prepared with 
Illumina Stranded mRNA Prep kit. RNA (25 ng per sample) were converted to cDNA by 
reverse transcription and adapters were ligated to cDNA fragments ends. This was 
followed by PCR, and RNAseq library is generated for sequencing. The libraries were 
sequences with 2 x 50 bp chemistry by using Illumina NovaSeq6000 next-generation 
sequencer. Detailed protocol link is below. My aim here was to carry out the RNAseq 





An overview of the workflow of RNAseq data analysis starts from sequencing reads. 
(https://genomicservices.utu.fi/ffgc_secret_rstudio/) R studio server was used to process 
the raw output files from the RNAseq (detailed steps in the appendix). The sample files 
were according to the list of sample mentioned in Table 2. Galaxy cloud cluster was used 
as an environment for the downstream analysis of the RNA sequencing data. These reads 
were aligned to reference genome and assembled into transcripts with the help of de novo 
assembly or reference transcripts annotations (Dobin et al., 2013).The gene expression 
levels are estimated by counting number of reads that can be aligned to exon. Further, 
downstream RNAseq data analysis includes checking differential expression between 
samples.  
The data from RNA sequencing were FASTAQ files containing raw reads sequenced 
from NGS. The Quality Control was done with fastqc and multiqc and filtering and 
trimming with cutadapt tool. To check the aggregate quality of the data, Multiqc report 
was generated. The reads were aligned to the annotated reference genome with STAR 
aligner. The parameters were set to be for Paired as individual data sets. The forward and 
reverse reads were uploaded individually for each samples. A built-in index was used as 
28 
reference genome (GRCh38/ Hg 38). The Length of the genomic sequence around 
annotated junctions were set to be 100. MAPQ value for unique mappers was set to be 
60. Others were default settings.  
To identify the genes affected by dexamethasone treatment, Deseq2 was used. The 
DESeq2 result files were by default in tabular format and it is supported by 
AnnotateMyIDs. Both the result files, 48h and 72h were uploaded in different runs. The 
annotation of the gene IDs was added, and the files were merged using join two data sets.   
From the filtered data of 48h and 72h, gene symbols were uploaded into the query of the 
g: profiler. It was uploaded as a set of 3 runs. In the first run, filtered gene symbols from 
48h were uploaded and run. Followed by 72h. The third run was performed with the 48h 
and 72h together, to compare the results based on its p values. “>” symbol is to be added 
in the beginning of the query for 48h and 72h respectively. The results are generated. First 
three runs were based on over-representation analysis for each of the three files 
separately. The CSV results were downloaded. The next three set of runs are for gene set 
enrichment analysis for individual files. The genes were arranged based on their p values 
from smallest to largest. The gene list was uploaded on the query window and ordered 
query is selected for the run. The output files were saved in CSV format. This was 
performed for the upregulated and downregulated genes to investigate the most 










3. Results  
The objectives of this study were to determine DNA methylation status of glucocorticoid 
receptor gene (NR3C1), as it may influence responsiveness of the cells to glucocorticoids 
and may become downregulated in response to glucocorticoid treatment. The DNA 
methylome and transcriptome changes that are caused due to glucocorticoid 
(dexamethasone) treatment at different time points were studied to understand the 
glucocorticoid response. The differential gene expression analysis was carried out to 
understand the upregulation and downregulation of the specific genes.  
3.1 DNA methylation status of glucocorticoid receptor gene 
The assay was successfully performed. However, we did not find any methylation in any 
of the 16 samples. The samples were treated at 48 hours and 72 hours considering the 
half-life of dexamethasone. As we know that during bisulfite conversion, unmethylated 
cytosines are converted into uracil and further it gets converted to thymines. However, 
for our results, we were able to see the pyrogram peak in the T nucleotide which were not 
an actual thymine base but an unmethylated cytosine conversion to thymine. In case of 
methylation, the cytosine would have been protected from conversion and the pyrogram 
peak could be visible for C.  
We can conclude from the targeted bisulfite pyrosequencing that the leukemia cells when 
treated at 48-hour time point, it did not show any changes in the DNA methylation status. 
For 72-hour time point, also we did not get any significant changes. The results from the 
pyrogram states that the control samples and dexamethasone samples treated at 48 hour 
and 72 hours were not significantly different from each other. The DNA methylation 
status showed 1% methylation in majority of the sites showing response to 
dexamethasone treatment.  The treatment does not cause epigenetic silencing of the 
NR3C1 gene through DNA methylation. It is also important finding that the region was 
hypomethylated in these cells which was not known earlier. This indicates that the cells 
are most likely responsive and not resistant to the glucocorticoid treatment.  
3.2 DNA methylome analysis 
In the case of RRBS data, majority of the reads should be mapped to CpG rich areas (such 
as promoters), since MspI enzyme targets and enriches those sites. However, based on 
our results, the MspI -enzyme digestion had not worked and reads mapped randomly to 
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the genome, instead of mapping only to the CpG rich regions. Also the commercial kit 
that was used for the RRBS library preparation was new. Although, the library preparation 
was successfully performed, but the MspI enzyme digestion did not work. Therefore, we 
did not get successful outcome of the results and the analysis was not continued for this 
data. The protocol with the new kit requires further optimization. 
3.3 RNA sequencing analysis  
To understand the gene expression changes that are caused by glucocorticoids treatment, 
the RNA sequencing analysis was performed. For the downstream analysis of the 
sequencing data, bioinformatics tools were used.  
3.3.1 Results of quality of the reads using FastQc tool and MultiQC tool  
 
 
Figure 4: The MultiQC report (v 1.7) generated an output (figure 3) with basics statics. 
(A) Sequence length distribution for the samples were range from 35 to 50bp. (B) 
Sequence counts shows the percentage as well as reads count of unique and duplicate 
reads (C) Per sequence quality score shows the quality of reads (D) GC content of the 
sequences.  
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The FastQC analysis was performed to check the quality controls of raw sequencing data 
produced from high through put sequencing. The MultiQC tool was used to visualize the 
FastQC outputs in a single report (Figure 4). The results of the MultiQC report for FastQC 
results shows, 32 samples had less than 1% overrepresented sequences. No sample was 
found with any adapter contamination > 0.1%. Sequence length distribution for the 
samples ranged from 35 to 50bp (Fig 4 (A)). The percentage of base calls at each position 
for which an N was called is displayed under per base N count. Sequence counts shows 
the percentage as well as reads count of unique and duplicate reads (Fig 4 (B)). Per 
sequence quality score shows the quality of reads which was good quality for our data 
(Fig 4 (C)). Per Sequence GC Content represents the GC content of the samples (Fig 4 
(D)). Per sequence base content represents the percentage of the nucleotides in the 
sequence. The MultiQC results from the Quality control using FastQC shows that there 
was no adapter contamination and the quality of the sequenced reads were also good to 
be proceed with the Mapping. The full report can be found in the appendix. 
3.3.2 Mapping using STAR aligner  
The STAR aligner was used to map the reads to the reference genome (human genome, 
hg 38). The number of raw reads mapping to unique or multiple location reference 
genome is shown in the Figure 5.  The approximate range of the input reads were between 
22M to 30M (millions). The range of uniquely mapped reads to the reference genome 
was between 15 M to 25 M. Average input read length was 98 and average mapped length 
was 97. The percentage of mismatch rates were very negligible. Hence, the results from 
mapping were acceptable.  
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Figure 5: Mapping of the reads against reference genome using STAR 
3.3.3 Principal component analysis to examine the clustering of samples 
Principle component analysis was performed as a part of the DESeq2 analysis to examine 
clustering of the samples.The figure 6 (A) shows that for the components at 48 hours 
control vs dexamethasone, the variance PC1 was 74%. The biggest variance is between 
the treated and control samples. This is what was to be expected that the control samples 
get cluster together and dexamethasone treated samples should cluster together. There is 
an exception for one outlier. However, the variance for the PC2 is not very high. If the 
outlier is neglected, this could affect PCA variance. 
There was is outlier in Figure 6 (B). The PC1 variance is 93% which indicates that the 
control samples have high variance to the dexamethasone treated samples at 72 hours. 
The variance at 72 hours is comparatively bigger than variance of 48 hours. But, PC2 is 





Figure 6: (a) PCA variance between control sample vs dexamethasone treated at 48 hours 
(b) PCA variance control samples vs dexamethasone treated at 72 hours.  
 
Dispersion estimates generates an interactive graph and is useful tool for diagnostics. It 
represents that the final estimates are shrunk towards the fitted estimates from gene wise 
estimates. The figure 8, shows the dispersion estimates at 48 hours and 72 hours. The x 
axis represents normalized counts and y axis represents the dispersion. Figure 7 (A) shows 
that dispersion is smoothly decreasing for the genes that has higher expression. This 
signifies the biological variability in the data. Hence, the data is reliable. However, there 
can be some false positives among the differentially expressed genes with high mean 
counts. Similarly, for the 72 hours (fig 7 (B)) the data smoothly aligns to the curve 
indicating high biological variability and reliable data.  
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Figure 7: Dispersion estimates (A) dispersion estimates for 48 hours (B) dispersion 
estimates for 72 hours.  
 
DESeq2 additionally also generates the heat maps for sample clustering. The provided 
heat maps indicate the similarities and dissimilarities between the samples. As shown in 
figure 8, the results indicate that dexamethasone treated samples are clustered together 
for 48 hours as well as 72 hours. Whereas control samples are also clustered together for 
both the time points respectively.  
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Figure 8: The heat maps were generated (A) shows 48 hours clustering of control vs 
dexamethasone samples (B) shows 72 hours clustering of control vs dexamethasone 
treated samples.  
3.3.4 Gene expression changes caused by glucocorticoid treatment in TALL cells 
The mapped reads used as input for DESeq2 resulted into list of 28,395 genes. The genes 
with adjusted p-values above 0.05 (>0.05) were excluded and genes with absolute fold 
change below 1.4 (<1.4) were excluded. Using this filtering criteria, 538 genes were 
upregulated at the 48 hours dexamethasone treated samples whereas 1669 genes were 
upregulated at 72 hour dexamethasone treated samples. There were 2119 genes 
downregulated at 48 hours and 3290 genes downregulated at 72 hours. Based on the gene 
names, there were 179 genes that were upregulated at both the times points and 886 genes 
were downregulated at both the times points. These data show that the genes were 
differentially expressed (table 7). (Top 100 names of the genes in appendix). 
Table 7: Most significant DEGs showing upregulations and downregulations at both the 















































































Among the differentially expressed genes that were identified from our studies BTG1 and 
BTG2 are the most significant and upregulated. They are responsible for the cell division, 
DNA repair, transcriptional activities regulation and stability of mRNA (Yuniati et al., 
2019). BTG proteins participates in maintain homeostasis. It has been reported that BTG1 
and BTG2 are often mutated or deleted in cancer cells.  The loss of these proteins is 
responsible for inducing tumour. The upregulation of these proteins shows response for 
growth factors and glucocorticoids and regulation of cellular homeostasis (Yuniati et al., 
2019). This study strongly supports our findings that BTG1 and BTG2 are upregulated at 
48 hours and 72 hours dexamethasone treatment showing response to glucocorticoids.  
TSC33d3 gene is activated by glucocorticoids and interleukin 10. It is crucial for anti-
inflammation as it interacts with pro-inflammatory TFs and activator proteins. This also 
has immunosuppressive effects for glucocorticoids and leads to transcriptional repression 
in several genes (Vandevyver et al., 2014). FKBP5 is known to be a strong inhibitor of 
GR function. Dexamethasone treatment can cause FKBP5 expression in tissues to be low 
and it is reported as negative regulator of GR sensitivity (Galat, 2004). 
 
3.3.5 Functional enrichment studies using g: Profiler  
The list of upregulated 538 genes for 48-hour treatment and 1669 for 72 hours treatment 
gene IDs were uploaded on g: profiler, (g: GOSt) in the input query using g: SCS 
algorithm and 0.05 p value for individual set of gene lists. The objective was to study the 
differential gene expression of dexamethasone treated cells at two different time points. 
The top most genes in the list represents highly significant and over expressed genes. This 
is used to study the related phenotypic difference causing the disease. The upregulated 
and downregulated genes were used for the input query in g: profiler to investigate the 
most significant results that based on adjusted p values to understand the gene ontologies 
and pathways. From the results, we also find the most significant enriched terms and 
pathways. As shown in table 10, and table 13 the comparative study of the gene 
expression was carried out at both the time points for upregulated and downregulated 
genes respectively. The most significantly enriched terms present in both the time points 
is shown.  
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Figure 9: (A) g: GOst functional profiling for 48 hours up regulated genes. The figure 
shows the details on enriched biological process, pathways, regulatory motifs, and 
proteins complexes. Manhattan plots generated by hypogeometric test by g: profiler. The 
X axis shows functional terms grouped and colours are assigned by the data source. The 
coloured dots on the plot are fixed and shows from the same branch related. Each dot 




Figure 9 (B): g: GOst functional profiling for 72 hour upregulated genes. The figure 
shows the details on enriched biological process, pathways, regulatory motifs, and 




Figure 9 (C): Multiquery for 48 hours and 72 hours upregulated genes for over 
representation analysis. The figure shows the details on enriched biological process, 
pathways, regulatory motifs, and proteins complexes 
As shown in figure 9 (A) the total number of terms for 48 hours that were significantly 
enriched are: GO: molecular functions (3), biological process (12), Cellular components 
(19), reactome (1), Transfac (54), HPA (100) and corum (1). The most significant terms 
are given in table 8.  
Table 8: The functional enrichment of gene ontologies and pathways for upregulated 
genes at 48 hours dexamethasone treatment.  
48 hours treated samples Significantly enriched 
terms  
Adjusted p values 
GO: Molecular Function RNA binding 3.292 x 10-3 
 ubiquitin protein ligase 
binding 
6.077 x 10-3 
 ubiquitin- like protein 
ligase binding 
1.52 x 10-2 
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GO: Biological process ncRNA metabolic process 1.172 x 10-7 
 ncRNA processing 1.014 x 10-5 
 ribosome biogenesis 1.213 x 10-3 
GO: Cellular components intracellular anatomical 
structure 
1.363 x 10-8 
 cytoplasm 2.750 x 10-8 
 membrane bound 
organelle 
1.052 x 10-5 
TRANSFAC Factor: E2F GGCGSC 6.776 x 10-6 
 Factor: E2F-1; Elk-1 2.790 x 10-5 
 Factor: GCMa: Erg 4.378 x 10-5 
HPA Tonsil; non germinal 
center 
4.137 x 10-10 
 Tonsil 1.421 x 10-9 
 Spleen  3.232 x 10-8 
 
As shown in figure 9 (B), the functional enrichment for 72 hours treated samples shows 
significantly enriched terms. Molecular function (28), biological process (100), cellular 
components (58), KEGG (15), Reactome (62), WP (5), Transfac (106), miRNA (8), HPA 
(100), corum (2) and HP (9).  Highly significant terms are shown in table 9. 
Table 9: The functional enrichment of gene ontologies and pathways for upregulated 
genes at 72 hours dexamethasone treatment.  
72 hours treated samples Significantly enriched 
terms  
P Adjusted values 
GO: Molecular Function Protein binding 6.868 x 10-14 
 RNA binding 1.391 x 10-9 
 Structural component of 
ribosome 
2.390 x 10-9 
GO: Biological process Cellular metabolic process 1.933 x 10-16 
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 Cellular component 
organization or biogenesis 
2.100 x 10-15 
 Organelle organization 2.197 x 10-15 
GO: Cellular components Intracellular anatomical 
structure 
2.455 x 10-46 
 Intracellular membrane- 
bounded organelle  
5.218 x 10-40 
 Intracellular organelle  9.386 x 10-40 
TRANSFAC Factor: E2F-3: HES-7 6.762 x 10-31 
 Factor: E2F-4 4.160 x 10-30 
 Factor: ZF5 5.287 x 10-29 
HPA Tonsil  1.686 x 10-40 
 Placenta 3.015 x 10-37 





Table 10: The functional enrichment of gene ontologies and pathways for 48 hours treated 
samples and 72 hours treated samples shows significant enrichment terms 
 
Both timepoints ( 48 
hours & 72 hours)  
Significantly 
enriched terms  
Adj p values 48 
hours 









1.479 x 10-2 1.933 x 10-16 
 Cellular component 
organization or 
biogenesis 
3.455 x 10-3 2.100 x 10-15 
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 Metabolic process 2.021 x 10-3 1.799 x 10-11 
 Ribonucleoprotein 
biogenesis 
5.092 x 10-3 4.438 x 10-11 
 Ribosome 
biogenesis 









1.076 x 10-5 5.218 x 10-40 
 Intracellular 
organelle  
1.460 x 10-4 9.386 x 10-40 
 Membrane bound 
organelle 
1.052 x 10-5  2.754 x 10-33 
TRANSFAC Factor: E2F-3: HES-
7 
5.810 x 10-5 6.762 x 10-31 
 Factor: E2F-4 5.735 x 10-5 4.160 x 10-30 
 Factor: ZF5 3.126 x 10-3 5.287 x 10-29 
HPA Tonsil 1.421 x 10-9 1.686 x 10-40 
 Placenta 3.210 x 10-4 3.015 x 10-37 




Figure 10 (A) g: GOst functional profiling for 48 hour down regulated genes. The figure 
shows the details on enriched biological process, pathways, regulatory motifs, and 
proteins complexes 
 
Figure 10 (B) g: GOst functional profiling for 72 hour down regulated genes. The figure 




Figure 10 ( C) ) Multiquery  g: GOst functional profiling for 48 hours and 72 hour down 
regulated genes. The figure shows the details on enriched biological process, pathways, 
regulatory motifs, and proteins complexes 
As shown in figure 10 (A), the total number of terms for 48 hours that were significantly 
enriched are: GO: molecular functions (36), biological process (94), Cellular components 
(48), reactome (12), KEGG (2), Transfac (587), miRNA (7), HPA (227) and corum (4) 
and HP (5). The most significant terms are given in table 11 
Table 11: The functional enrichment of gene ontologies and pathways for downregulated 
genes at 48 hours dexamethasone treatment.  
48 hours treated samples  Significant enriched terms  P Adjusted values 
GO: Molecular function Nucleotide binding  9. 297 x 10-14 
 Nucleoside phosphate 
binding 
9.956 x 10-14 
 Purine nucleotide binding  4.893 x 10-13 
GO:Biological processes  Cellular metabolic process 2.279 x 10-17 
 Nitrogen compound 
metabolic process 
6.831 x 10-14 
 Primary metabolic process 6.281 x 10-13 
GO: Cellular component Intracellular anatomical 
structure 
1.909 x 10-40 
 Intracellular membrane 
bounded organelle  
3.234 x 10-31 
 Cytoplasm 7.799 x 10-31  
TRANSFAC Factor: E2F-4  2.736 x 10-37 
 Factor: ZF5 3.408 x 10-37 
 Factor: E2F-3:HES-7 9.201 x 10-36 
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HPA Tonsil 6.949 x 10-32 
 Colon 1.095 x 10-31 
 Placenta 2.044 x 10-30 
 
As shown in figure 10 (B), the total number of terms for 72 hours that were significantly 
enriched are: GO: molecular functions (43), biological process (219), Cellular 
components (79), reactome (43), KEGG (13), Transfac (810), miRNA (11), HPA (264) 
and corum (2) and HP (44). The most significant terms are given in table 12. 
Table 12: The functional enrichment of gene ontologies and pathways for 72 hours down 
regulated samples shows significant enrichment.  
72 hours treated samples Significantly enriched terms P adjusted values  
GO: Molecular function Protein binding 2.016 x 10-25 
 RNA binding 1.851 x 10-14 
 Catalytic activity 4.570 x 10-13 
GO: Biological process Cellular metabolic process 4.787 x 10-39 
 Cellular component 
organization or biogenesis 
4.146 x 10-26 
 Metabolic process 5.998 x 10-26 
GO: Cellular compnents Intracellular anatomical 
structure 
4.231 x 10-86 
 Intracellular membrane 
bound organelle  
1.676 x 10-67 
 Cytoplasm 1.407 x 10-64 
TRANSFAC Factor : ZF5 3.920 x 10-76 
 Factor: E2F-3:HES-7 3.190 x 10-66 
 Factor: E2F 3.714 x 10-66 
HPA Appendix  4.079 x 10-67 
 Tonsil 1.214 x 10-65 






Table 13: The functional enrichment of gene ontologies and pathways for 48 hours treated 
samples and 72 hours down regulated samples shows most significant enrichment terms. 
 





P adjusted at 48 
hours 




Protein Binding 9.217 x 10-7 1.813 x 10-25 
 RNA binding 1.095 x 10-9 1.77 x 10-14 





2.279 x 10-17 3.881 x 10-39 
 Cellular component 
organization or 
biogenesis 
3.180 x 10-12 3.142 x 10-26 









3.234 x 10-31 1.676 x 10-67 
 Cytoplasm 7.799 x 10-31 1.407 x 10-64 
TRANSFAC Factor: ZF5 1.027 x 10-32 3.920 x 10-76 
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 Factor:E2F-3:HES-7 9.201 x 10-36 3.190 x 10-66 
 Factor E2F-2 2.293 x 10-28 3.714 x 10-66 
HPA Appendix 1.325 x 10-26 4.079 x 10-67 
 Tonsil 6.949 x 10-32 1.214 x 10-65 
 Pancreas  7.968 x 10-25 1.121 x 10-58 
The above results from the g: profiler, gives the functional significance of gene expression 
changes for the cells. The most significant gene ontologies and pathways that are 
potentially affected by dexamethasone treatment at 48 hours and 72 hours is shown in 
table 8 to table 13 for upregulated and downregulated set of queries respectively. The 
most significant transcription factors are E2F with different motifs and class that acts as 
both, an activator and repressor of transcription. It also participates in cell proliferation 
and differentiation as well as tumor suppression and oncogenesis (Dimova, 2005). ZF5 
transcription factor regulates the expression of mammalian genes with GCC triple repeats 
in 5’ regulatory region on HepG2 cells (Orlov et. al., 2006). The most significant cellular 
components that are enriched at both the timepoints in upregulation and downregulation 
are intracellular anatomical structure, intracellular membrane bounded organelle and 
cytoplasm. These top three highly significant cellular components are most affected by 
dexamethasone treatment. However, also Human protein atlas (HPA) was also highly 




The objective of this study was to determine the molecular mechanism of dexamethasone 
response in pediatric T-ALL cells as glucocorticoids are crucial for therapeutics in T-
ALL. The study was conducted to understand the DNA methylation and gene expression 
changes caused by glucocorticoid treatments in ALL cells. The DNA methylation status 
of NR3C1 gene was checked in T-ALL cells.  
4.1 DNA methylome changes by glucocorticoid treatment 
DNA methylation changes caused by glucocorticoids treatment in T-ALL cells were 
studied. In the case of RRBS data, majority of the reads should be mapped to CpG rich 
areas (such as promoters), since MspI enzyme targets and enriches those sites. However, 
based on our results, the MspI -enzyme digestion had not worked and reads mapped 
randomly to the genome, instead of mapping only to the CpG rich regions. Also, the new 
commercial kit was used for the RRBS library preparation. The library preparation in 
general was successful but the MspI enzyme digestion was not successful. The new 
commercial kit might further have to be optimized yet. Therefore, we did not get 
successful outcome of the results and the analysis was not continued for this data. 
4.2 DNA methylation status of NR3C1 
DNA methylation status of NR3C1 in T-ALL cells was studied. Targeted bisulfite 
pyrosequencing was performed to measure DNA methylation status of NR3C1 gene. 
There was no methylation in any of the 16 samples. The samples were treated at 48 hours 
and 72 hours considering the half-life of dexamethasone. The results show 1% 
methylation in majority of the sites. Based on these results the cells are most likely 
responsive to dexamethasone treatment. In our study, the treatment does not cause 
epigenetic silencing of the NR3C1 gene through DNA methylation. The selected CpG site 
was hypomethylated in these cells.   
Previous findings have reported that NR3C1 causes reduced gene expressions. There is a 
link between gene expressions and the methylation at promoter region of NR3C1 causing 
transcription silencing of the gene (Watkeys et al., 2018). Dexamethasone exposure may 
lead to silencing of the gene encoding for the receptor and impaired glucocorticoid 
response. Our study shows that the cells are most likely responsive to dexamethasone 
treatment and not resistant to the glucocorticoid treatment. This is an interesting finding 
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based on our study that hypomethylation in cells prevents epigenetic silencing of NR3C1 
gene.  
4.3 Differential gene expressions caused by glucocorticoid treatment 
From our study, there are, 2119 downregulated genes for 48 hours treatment and 3290 
downregulated for 72 hours. TSC22D3, PIK3IP1, FKBP5, RCAN1, DDIT4, ISG20 and 
DPEP1 are downregulated at 48 hours whereas, DDIT4, TNFSF8, MACROD2, EPGN, 
PFKFB2 and RUNX2 are downregulated at 72 hours. 
TSC22D3 encodes for the anti- inflammatory protein GC induced leucine zipper. This 
gene shows expression in response to GCs and IL-10. It has immunosuppressive effects 
for the GCs (Ayroldi et al., 2001). It is majorly involving cellular differentiation or 
apoptosis. This indicates the tumor promoting function of the gene causing cancer. IL-10 
produces T- regulatory cells that are induced by GCs and can inhibit the T-cells responses 
(Miller et. al, 2007). Previous studies reported that TSC22D3 can be upregulated by GCs. 
On contrary recent studies have shown the role of TSC22D3 during T-cell activation and 
its interaction with NF-kB. This shows TSC22D3 can inhibit the T-cell receptor induced 
Interleukin receptor expressions as well as NF-kB activity (Miller et. al, 2007). TSC22D3 
inhibits the NF-kB transcriptional activities and DNA bindings as TSC22D3 interferes 
with NF-kB subunits. Also T- cell receptors responses that are influenced by TSC22D3, 
results into down regulation of gene expression (Miller et. al, 2007). This is a newly 
identified molecular mechanism that signifies the dexamethasone induced regulation of 
T-cell activation and NF-kB activities. However, this gene is highly influenced by GCs 
in majority of leukemia cells causing either apoptosis sensitivity or resistance (Miller et. 
al, 2007). Thus, TSC22D3 gene expression alone is not reliable to justify the indicator of 
GC sensitivity.  
FKBP5 is known to be a strong inhibitor of GR function. Dexamethasone treatment can 
cause FKBP5 expression in tissues to be low and it is reported as negative regulator of 
GR sensitivity (Galat, 2004).  FKBP5 and RCAN1 are prime candidates for genes that 
are regulated by GCs in lymphocyte as RCAN1 protects T-cells from GC induced 
apoptosis (Nagao et al., 2012). FKBP5 interact with GR via Hsp90 and interferes nuclear 
translocation of GR. RCAN1 is strong indicator of dexamethasone induced transcription 
reported to be causing calcium stress (Nagao et al., 2012). Thus, FKBP5 and RCAN1 are 
crucial genes that indicated GC sensitivity and GC mediated apoptosis. Previous studies 
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have reported that the over expression of RCAN1 can influence apoptosis when induced 
by GCs (Nagao et al., 2012). On contrary, in our study the FKBP5 and RCAN1 are 
downregulated suggesting no GC mediated apoptosis. DDIT4 functions similar to FKBP5 
and the downregulation suggests reduced or no GC mediated apoptosis (Schmidt et al., 
2016).  
From our study, there were 538 upregulated genes at 48 hours that includes BTG2, 
TP53INP1, SLC22A23, PTPRM, HS3ST4 and RSAD2. Whereas 1669 upregulated genes 
at 72 hours includes, BTG1, USP20, MYOB1, PLXNB1, CCDC88B and CD53.  
BTG1 and BTG2 are the most significantly upregulated genes at 72 hours and 48 hours 
respectively. BTG1 and BTG2 are one of the most essential proteins and have important 
roles in cellular differentiation process and metabolic regulation (Yuniati et al., 2019) 
Deregulation of BTG1 and BTG2 results into malignancies and alterations causing 
prognosis leading to disease (Van Galen et al., 2010). It has been reported that BTG1 and 
BTG2 are often mutated or deleted during malignancies.  The loss of these proteins is 
responsible for inducing tumour. The upregulation of these proteins shows a positive 
response for growth factors and glucocorticoids and regulation of cellular homeostasis 
(Yuniati et al., 2019).  
 
Functional enrichment analysis using g: profiler was that several GO such as molecular 
functions, biological processes, and pathways were significantly enriched. The most 
enriched terms were Transcription factors (EF2 with different motifs and ZF5) and 
cellular components (intracellular anatomical structure, intracellular membrane bounded 
organelle and cytoplasm). From the functional enrichment studies in g: profiler, the highly 
significant p values indicate the most outstanding gene ontologies functions in molecular 
functions, biological process and cellular components and pathways. These most 
significant terms are identified as most affected by dexamethasone treatment at respective 
time points. Corresponding to these finding from g: profiler, one of the important protein, 
TP53INP1 that is regulated by p53 and E2F1 transcription factors. As mentioned above, 
E2F1 transcription factors are responsible for huge number of gene expression regulations 
and is necessary for progression from G1 to S (Weinberg, 2011) and increased in the 
activity of E2F1 transcription factor correlated with increase in the expression of 
TP53INP1 and other apoptosis co factors. In our results TP53INP1 is upregulated by 
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dexamethasone treatment. This also validates the results that, the highly significant 
transcription factors from our functional enrichment studies (E2F) are responsible for the 
upregulation of TP53INP1. 
Among the upregulated genes, SLC22A23 is the new identified candidates that is 
upregulated by glucocorticoid and have not been previously linked with T-ALL. 
SLC22A23 is upregulated at both the time points. It belongs to a transmembrane protein 
family. It works as transporters like uniporters, symporters and/or antiporters for cell 
membranes. It is generally associated with diseases like Laryngeal Benign Neoplasm 
(Jacobson et al, 2007). From Gene Ontology studies, it has been observed to be involved 
in transmembrane transporter activity. However, not much is known about SLC22A23 
and further investigation is required to explore the mechanism and its role in T-ALL.  
To summarize the findings, the DNA methylation status of NR3C1 showed 1% 
methylation at majority of its sites resulting that the treatment does not cause epigenetic 
silencing of NR3C1 gene through DNA methylation. This suggest that the region is 
hypomethylated which was not known earlier. As the treatment did not cause epigenetic 
silencing, this indicates that the cells were responsive to dexamethasone treatment and 
not GC resistant. To further investigate, the dexamethasone response causing gene 
expression changes, RNA sequencing was performed and the data was analysed to 
identify the differential gene expression changes and potential gene candidates that are 
linked with T-ALL. Based on previous reports, many genes have been associated with 
the upregulation and downregulation of gene expression in response to glucocorticoid 
treatment. However, from our study, we identified 538 upregulated and 2119 
downregulated genes for 48 hours treatment and 1669 upregulated genes and 3290 
downregulated genes for 72 hours treatment. Out of these genes, the most significant 
genes were identified. Also the function enrichment analysis was performed using g: 
Profiler. The upregulated genes and down regulated gene queries resulted into the list of 
GO and pathways that are most significant and most affected by dexamethasone treatment 
at respective time points. From our findings, transcription factors and cellular components 
were most affected by the treatment as it shows high significance and are enriched. In our 
study we show the differential gene expression changes that are caused by dexamethasone 
treatment in T-ALL cells results into alteration in the gene transcriptional activities.  
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5 Limitations and future aspects              
The study conducted to understand the molecular mechanism of glucocorticoids using 
bioinformatics pipelines to interpret the sequencing data has revealed information on 
differential gene expression changes. The mechanism of glucocorticoid resistance is still 
unknown and remains an important field of study in epigenetic research. The correlation 
between relapse of T-ALL and glucocorticoid resistance is also an interesting field of 
epigenetics. The unfavourable upregulation or downregulation of the genes in response 
to glucocorticoid treatment during cancer shows the link between glucocorticoid 
resistance. However, there is no clinical evidence to support this. The mechanism of how 
the downregulation or silencing of important cancer markers and proteins causes the 
tumor initiation and progression or its response to glucocorticoids could contribute a 
novel treatment or anticancer therapies with lesser toxic side effects.  
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Steps for the Bioinformatics pipelines: 
Processing the Raw data using Linux command line  
(https://genomicservices.utu.fi/ffgc_secret_rstudio/) server was used to process the raw output 
files from the RNAseq. The sample files were according to the list of sample mentioned in 
Table 2.  
To carry out the analysis, I used a few set of basic linux commands that were essential for 
processing of the data.  
pwd Prints the current working directory 
ls Lists contents of current directory 
ls -l Content of current directory in details 
cd Change directories to work directory 
mkdir Makes a new directory 
rmdir Removed a directory 
nano Opens a text editor  
cp  Copies myfile to myfile2. If already exists, over writes 
sbatch Submits a batch script to slurm  
sacct Displays the job status 
cat Concatenate the files 
 
Table: Linux command that were required for the analysis 
The raw files were made available on /wrk/students/shreya folder on the cluster. Next, pwd 
verifies the current folder (directory). A new directory was created, using mkdir command as 
a sub directory to the parent directory. Using cd command, the working directory was changed. 
This can be repeated if new directories are required. To check the content of the directory ls 
command was used.  
To make available, all the files in the working directory, I used cp command. This command 
copies the contents in the current directory. If already exists, it over writes. A path is to be 
designated to copy these files. ”. /” command at the end is for current directory where as ”. . /” 
this command redirects to the previous directory.  
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Once the files are copied succesfully using the path assigned to working computer system, 
these files are ready to be proceed with. The raw files in the folder named 
RD20006_mRNAseq_trimmed were next, concatenated using cat command. The example 
code for 16th sample file is shown below.  
 
[shjosh@ffgc02 RD20006_mRNAseq_trimmed]$ cat 
RD200006_16_16_D2W2_72h_25_S31_L001_R1_001006_16_16_D2W2_72h_25_S31_L0
02_R1_001.fastq.gz > combined_16_R1.fastq.gz  
[shjosh@ffgc02 RD20006_mRNAseq_trimmed]$ cat 
RD200006_16_16_D2W2_72h_25_S31_L001_R2_001006_16_16_D2W2_72h_25_S31_L0
02_R2_001.fastq.gz > combined_16_R2.fastq.gz 
Similarly, all the raw files were concatenated considering the forward reads and the reverse 
reads (R1 and R2). These concatenated files were downloaded to my computer from the cluster 
using power shell. The forward reads of one sample are concatenated (R1 with R1) and reverse 
reads of one sample are concatenated (R2 with R2) 
 These raw files were successfully concatenated using Linux command line. To further upload 
these files onto the server, they required to be downloaded from the cluster to own computer.  
rsync -av username@munin:/wrk/students/shreya/RD20006_mRNAseq_trimmed/*.fastq.gz 
~/Users/Dell/Desktop/Fastq files  
I used windows power shell command line for this and ready to be uploaded to the galaxy 
Europe server (https://usegalaxy.eu/). I used galaxy version 21.01 for my RNAseq analysis.  
 
Quality Control  
FastQC read quality reports (Galaxy version 0.72 + galaxy 1) was used to process the raw 
input files in fastq.gz format. The output of the FastQC is a basic text and an HTML output 
file. The produced results mentioned FastQC (version 0.11.8) Default parameter settings were 
as follows.  
 
Short read data from your current history: file name.fastq.gz 
Contaminant list: Nothing 
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Adapter list: nothing 
Submodule and Limit specifing file: Nothing  
length of Kmer to look for: 7 
 
 
Figure: The FastQc report shows the output file for sample 1, treated at 48h. The summary (on 
the left), displays the information provided by the FastQC.  
The FastQC output generates two types of files (webpage and raw data). The raw data of all 
the files was uploaded in MultiQC version 1.7 (optional) to get the aggregated quality report.  
 
Figure: MultiQC generated the aggregate result from multiple sample files into a single report. 
The figure shows, % duplicates, % GC contents and M seqs (total sequence in millions) 
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There was no requirement for trimming the reads as the quality reports were satisfactory.  
RNA STAR gapped- read mapper for RNA-seq data (version 2.1.8a) 
High through put sequencing requires mapping of the reads to a reference genome and this is 
one of the most crucial step of RNAseq pipeline. I used STAR aligner for mapping the reads 
on Galaxy Europe server. Generally, STAR is used as a software package that supports Linux 
command line. It is highly accurate with more speed compared to other tools. STAR is also 
efficient to provide results on novel spice junctions, chimeric and circular RNA. It is capable 
of aligning sequences of any length with minimum error. The output files generated from 
STAR is used further for downstream analysis to study differential gene expressions. However, 
it depends on the data and personal choice to select an appropriate tool for the workflow.  
Parameter settings as below. The output of RNA STAR generates 3 files. Log, mapped.bam 
and splice junction.bam 
Single-end or paired-end reads: Paired as individual data sets 
RNA-Seq FASTQ/FASTA file, forward reads: R1 files  
RNA-Seq FASTQ/FASTA file, reverse reads: R2 files  
Custom or built-in reference genome: Use a built-in index 
Reference genome with or without an annotation: use genome reference without built-in model 
Select reference genome: Human Dec 2013 (GRCh38/ Hg 38) 
Length of the genomic sequence around annotated junctions: 100 
Use 2-pass mapping for more sensitive novel splice junction discovery: no 
Per gene/transcript output: No per gene or transcript output 
Report chimeric alignments? No 
Read alignment tags to include in the BAM output: default  
HI tag values should be: 1 
MAPQ value for unique mappers: 60 
Exclude the following records from the BAM output: select all  
Would you like to set additional output filters? no 
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Configure seed, alignment and limits options: defaults   
 
Figure: The figure shows the RNA STAR log file as an example of the output for sample 1, 
treated at 48h. It gives the information about read, mapping of reads, unmapped reads and 
length of mapped reads.  
FeatureCounts- Measures gene expression in RNAseq from Sam or Bam files (Version 
2.0.1) 
Mapping the reads generates output in three different file formats. To carry further analysis to 
understand the gene features is also essential. Hence, for such analysis counting the number or 
reads is important part to understand the overlapping of genes. This counts are useful for 
downstream analysis in various tools that requires count based methods for differential gene 
expressions. FeatureCounts supports SAM or BAM files as input. The parameters settings were 
as below: 
Alignment file: mapped.bam files (Output from RNA STAR) 
Specify strand information: Default  
 
Gene annotation file: featureCounts built-in 
Select built-in genome: hg38 
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Output format: read count (MultiQc/Deseq2/edgeR/limma- voom compatible) 
There were two output files generated as summary and feature counts. The featureCounts files 
are compatible to be used as an input in DeSeq2 for differential gene analysis.  
 DESeq2- Determines differentially expressed features from count tables (version 
2.11.40.6) 
DESeq2 supports the featureCounts output files. Apart from this, it also supports HTSeq counts 
as input. It enables the users to analyse comparative RNAseq data by using shrinkage 
estimators which are required for dispersion and fold change. DESeq2 is a highly efficient, 
accurate and sensitive tool that can also control the false positives. The parameter settings of 
DESeq2 were as below: 
Select datasets per level 
Factor: Effects_Dexamethasone 
Factor level 1: Control 48h/ 72h 
Factor level 2: Dexamethasone 48h/ 72h 
Counts file(s): Individual files corresponding to the timepoints 
Files have header? Yes 
Choice of Input data: count 
Visualising the analysis results: yes 
Output normalized counts table: yes  
Remaining settings were set to default. The setting were individually followed for the input of 
the count files for 48 h and 72 h respectively. The output files generated were, DESeq2 results, 
plots and Normalized counts. The DESeq2 result files were downloaded for 48 h and 72 h and 
were further used for downstream study. 
AnnotateMyIDs- annotate a generic set of identifiers (3.12.0) and Join two Datasets (2.1.3) 
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The DESeq2 result files were by default in tabular format and it is supported by 
AnnotateMyIDs. Both the result files, 48h and 72h were uploaded in different runs. The 
parameter settings were as below: 
File with IDs: DESeq2 result files 48h/ 72h 
File has header? yes 
Organism: Human 
ID type: Entrez 
Output columns: Select, EntrezID, Symbol, Genename, Refseq 
Remove duplicates: yes 
The data sets were joined using Join two datasets tools. The output result file from DESeq2 
was joined with the corresponding annotation file by using Join Two Datasets tool. The 
parameters were as follows: 
 
Join: DeSeq2 result file  
Using column: 1 
With: Annotated corresponding file  
And column: 1 
Keep lines of first input that do not join with second input: yes 
Keep lines of first input that are incomplete: no 
Fill empty columns: yes 
Only fill unjoined rows: yes 
Fill columns by: single fill values 
69 
Fill values: default 
Keep headers: yes  
These result files were Downloaded and opened in excel. Filtering was done, by excluding all 
the rows/genes, which have adjusted p-value above 0.05. Also, excluding all the rows/genes, 
which have absolute fold change below 2 (I used 1.4 because, of lesser number of genes to 
proceed for functional enrichment studies). Both the filtered files (48 and 72 h) were uploaded 
to galaxy to identify the genes. Join two datasets tool was used again with the same parameters 
as above (Note: the columns joined were 9th column, based on the gene name). These files were 
saved in excel and the final step is function gene enrichment analysis. 
 
48 hours up 
regulated genes 
72 hours up 
regulated genes 
48 hours down 
regulated genes 
72 hours down 
regulated genes 
BTG2 
TP53INP1 
SLC22A23 
PTPRM 
HS3ST4 
RSAD2 
EOMES 
TAGAP 
SMOX 
PLAU 
ABTB1 
CORO1B 
GPR153 
PTPRE 
PARVG 
TFPI 
GRAMD4 
HSPD1 
CCDC88B 
ST3GAL6 
BTG1 
USP20 
SLC22A23 
MYO1B 
PLXNB1 
CCDC88B 
CD53 
FHL1 
SIDT1 
PALD1 
ABCA7 
TRANK1 
HSPD1 
RASAL3 
ELOVL4 
RASSF2 
CYTH4 
NBEAL2 
RGS12 
GABARAPL1 
TSC22D3 
PIK3IP1 
FKBP5 
RCAN1 
DDIT4 
ISG20 
DPEP1 
BTG1 
EPGN 
TUBA4A 
CDO1 
TNFSF8 
JUN 
RUNX2 
SLC18A2 
BTNL9 
BMF 
TXNIP 
ZFP36L2 
SOCS1 
DDIT4 
TNFSF8 
MACROD2 
TUBA4A 
EPGN 
PFKFB2 
RUNX2 
FKBP5 
ISG20 
DPEP1 
CD1A 
BTNL9 
ZFP36L2 
CDO1 
JUN 
CD1E 
HKDC1 
SMAP2 
BMF 
TAMALIN 
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SYNE1 
GDF10 
DTX1 
BCL2L1 
ALDH4A1 
TXK 
SEMA4D 
CD300A 
CCNG2 
CALCOCO1 
WFS1 
PTPN18 
MRTO4 
LINC00977 
CBFA2T3 
LINC00426 
PUS7 
APOBR 
CASP10 
CCDC71L 
CTSB 
CD93 
ATP6V0E2-
AS1 
DOK2 
FILIP1L 
S100A10 
KCNAB2 
HCST 
LEF1 
WDTC1 
NDST3 
TRIM71 
WFS1 
IFRD1 
LRP5 
PPP1R13B 
PTPRE 
FCGBP 
NLRP1 
DNTT 
C1RL-AS1 
NUAK1 
TECPR1 
HPCAL1 
RRM2 
MLXIP 
PIK3R5 
DGKG 
BAZ2B 
CTC1 
UTP4 
CFLAR 
PCSK7 
PARL 
ZNF469 
CAMK1D 
LINC01882 
PSPH 
MRPL3 
LCT 
GNA11 
FKBP4 
UNC93B1 
LINC01120 
PSD4 
CD1A 
TAMALIN 
ROR1 
CD1E 
MYO1B 
SMAP2 
NFIL3 
HKDC1 
HEMGN 
CDH23 
IL7R 
ITGA6 
GLUL 
CROCC 
ENDOD1 
SLA 
USP20 
GRAP2 
ARHGAP31 
UBASH3B 
NR3C1 
TSHR 
XKRX 
PRCD 
MYO15B 
FHL1 
CCR9 
CAMK1D 
TBKBP1 
PLXND1 
AMPD3 
KRT1 
CD8A 
GLUL 
RCAN1 
TXNIP 
ENDOD1 
SLC18A2 
MYO15B 
TSC22D3 
BTG2 
AREG 
PTPRM 
UBASH3B 
CD1B 
CDH23 
SOCS1 
XKRX 
TSHR 
H6PD 
ARHGAP31 
NFIL3 
DBNDD1 
CROCC 
FURIN 
TBKBP1 
TP53INP1 
LCT-AS1 
DNAH1 
SPOCK2 
ITGA6 
PLEC 
PRCD 
ZNF862 
EOMES 
LIPC 
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PLXDC1 
SEH1L 
MLXIP 
TECPR1 
PHLDB2 
KIRREL1 
UTP4 
GNL3 
PPP1R14B 
UTRN 
ELMO2 
SAT2 
PRMT7 
LOC105371430 
ADA 
YPEL3 
TRIM22 
NOL7 
OSBPL5 
CD1D 
MPP6 
ATF5 
BRIX1 
PNPT1 
CD1C 
ATP6AP1L 
ADAMTS10 
EBNA1BP2 
CFLAR 
SGK1 
CDHR1 
EIF5A 
HDAC7 
LINC00426 
MAN2B2 
TRUB1 
PDE3A 
FCMR 
GRPEL1 
TRIM71 
ARID5A 
DPEP2 
MINK1 
PSAT1 
SEC31B 
ACAT2 
PCNX1 
TOM1L2 
ARHGEF1 
ZSWIM4 
NA 
RAB11FIP4 
IDUA 
TSPOAP1 
AKAP13 
LINC00528 
ATG2A 
ENO1 
NOL7 
DLAT 
ST3GAL6 
ATP6V1B2 
CD69 
PLPP1 
HSPA8 
PGPEP1 
CD53 
METTL7A 
SPOCK2 
H6PD 
RCSD1 
RAG1 
BCL2L11 
RASAL3 
LOC101928304 
PBXIP1 
SIDT1 
FCMR 
DBNDD1 
HES4 
CCR4 
PTK2B 
CSGALNACT1 
NKX3-1 
ALOX5AP 
ARID5A 
SLFN5 
CYTIP 
DNAJB2 
UGT3A2 
SMPD1 
RASD1 
ASXL2 
ETV5 
DAAM2 
ATP6V0E2 
CD79A 
RGMA 
FURIN 
CD93 
CD8A 
LOC101928304 
GRAP2 
SLA 
CD1C 
KCNAB2 
PLXDC1 
AMPD3 
RCSD1 
APOBR 
IGLL1 
SEMA4D 
PTK2B 
RAG1 
NR3C1 
ASXL2 
PNMT 
UBA7 
FGFR1 
SHQ1 
HES4 
JAK3 
GPR153 
CCDC136 
IL32 
KRT1 
IQGAP2 
ZSWIM8 
SLFN5 
PTPN18 
PARVG 
IL7R 
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AKAP13 
AIMP2 
SKA3 
MRPL4 
PDE1B 
SESN1 
IL32 
JAK1 
JAK3 
WT1 
SSB 
DUSP10 
CALR 
GRPEL1 
 
HEMGN 
TMEM63A 
STAMBPL1 
STS 
CCT3 
KDM7A 
CCDC102A 
YOD1 
MYO9B 
SLC8B1 
TCP1 
BYSL 
TRIM56 
 
GVINP1 
MCHR1 
FGFR1 
RBM38 
KLHL36 
IQGAP2 
MXD4 
IFRD2 
MACROD2 
RGS12 
NLRP1 
LBH 
PLXNB1 
 
OLFM2 
TSPAN5 
PBXIP1 
TRPM2 
CCT5 
SMPD1 
RASD1 
GVINP1 
HS3ST4 
PRTFDC1 
DNAJB2 
MTHFD2 
FAM216A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
 
 
 
 
 
 
 
 
 
